Clinical trials · Raleigh–Durham, NC
Leukemia clinical trials in Raleigh–Durham
We’re tracking 69 recruiting leukemia studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chapel Hill, North CarolinaAges 13 years+ - NCT07634653Recruiting
Strength Training for Kids with Newly Diagnosed Blood Cancer
This study tests whether strength training exercises during cancer treatment can help children with acute lymphoblastic leukemia or lymphoblastic lymphoma feel stronger and recover better. The research includes optional interviews with parents to understand how the program affects families.
Chapel Hill, North CarolinaAges 6 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Chapel Hill, North CarolinaAges 13–90 - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06296368Recruiting
A tool to help older adults make cancer care decisions
This trial tests if a special tool can help adults aged 60 and older who are newly visiting a blood cancer or bone marrow transplant clinic understand their options and make decisions that fit their needs.
Chapel Hill, North CarolinaAges 60 years+ - NCT04895436RecruitingPhase 2
Oral venetoclax plus IV obinutuzumab after prior CLL treatment
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
Chapel Hill, North CarolinaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chapel Hill, North CarolinaAges Any age - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Chapel Hill, North CarolinaAges 18–66 - NCT01137643Recruiting
Sharing blood and tissue samples for blood cancer research
This trial collects tissue, blood, and other body fluid samples from people with blood-related cancers. The goal is to help researchers study these diseases by building a source of samples for future testing.
Chapel Hill, North CarolinaAges 18–120 - NCT06222580RecruitingPhase 1
Combination of two targeted drugs for resistant FLT3-mutated AML
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Chapel Hill, North CarolinaAges 18 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT03013998RecruitingPhase 1/Phase 2
Biomarker-guided treatment study for older adults with AML
This trial studies whether choosing treatment based on lab test “biomarkers” (specific genetic or blood markers) can help people with acute myeloid leukemia (AML). It focuses on adults who are not good candidates for the most intensive chemotherapy, and it uses different sub-studies for different AML types.
Chapel Hill, North CarolinaAges 18 years+ - NCT06860880Recruiting
Personalized program to fight cancer-related fatigue
This trial tests a personalized supportive care program that combines exercise, nutrition, and coaching to help reduce fatigue in people with certain slow-growing lymphomas. It aims to improve energy and quality of life.
Chapel Hill, North CarolinaAges 18 years+ - NCT05442216RecruitingPhase 2
Study of tagraxofusp, azacitidine, and venetoclax for secondary AML
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
Chapel Hill, North CarolinaAges 18 years+ - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Chapel Hill, North CarolinaAges 12 years+ - NCT03717844Recruiting
Registry for adults with plasma cell disorders
This study is a registry that collects information about adults with plasma cell disorders (conditions involving abnormal antibody-producing cells). It may help researchers understand these diseases better and improve future care by tracking patients over time.
Chapel Hill, North CarolinaAges 18 years+ - NCT06652438RecruitingPhase 3
Revumenib plus standard drugs for NPM1 or KMT2A AML
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
Chapel Hill, North CarolinaAges 18 years+ - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Chapel Hill, North CarolinaAges 18–75 - NCT06043674RecruitingPhase 2
Glofitamab alone or with other drugs for Richter's transformation
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
Chapel Hill, North CarolinaAges 18 years+ - NCT05401097RecruitingPhase 2
Venetoclax plus IDH-targeted pills for AML patients who can’t get intensive chemo
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Chapel Hill, North CarolinaAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Chapel Hill, North CarolinaAges 18 years+
Hear when a new Leukemia trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Leukemia trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting leukemia studies listed above.
- University of North Carolina at Chapel Hill · 13 studies
- UNC Lineberger Comprehensive Cancer Center · 4 studies
- Massive Bio SYNERGY-AI site
- North Carolina Basnight Cancer Hospital
- North Carolina Cancer Hospital
- US-Chapel Hill-UNCNORTHCAROLINA
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting leukemia studies in North Carolina.
Common questions
- Are there leukemia clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 69 recruiting leukemia studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.